International Journal of Nanomedicine,
Journal Year:
2022,
Volume and Issue:
Volume 17, P. 869 - 900
Published: Feb. 1, 2022
Abstract:
Persistent
infection
with
high-risk
human
papillomaviruses
(HPVs),
such
as
HPV-16
and
HPV-18,
can
induce
cervical
cancer
in
humans.
The
disease
carries
high
morbidity
mortality
among
females
worldwide.
Inoculation
prophylactic
HPV
vaccines,
Gardasil
®
or
Cervarix
,
is
the
predominant
method
of
preventing
6
to
26
years
age.
However,
despite
availability
commercial
no
therapeutic
vaccines
eliminate
existing
infections
have
been
approved.
Peptide-based
which
form
one
most
potent
vaccine
platforms,
broadly
investigated
overcome
this
shortcoming.
are
especially
effective
inducing
cellular
immune
responses
eradicating
tumor
cells
when
combined
nanoscale
adjuvant
particles
delivery
systems.
This
review
summarizes
progress
development
peptide-based
nanovaccines
against
infection.
Keywords:
papillomavirus,
cancer,
nanovaccine
Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(25)
Published: April 26, 2024
Cancer
vaccines
offer
a
promising
avenue
in
cancer
immunotherapy
by
inducing
systemic,
tumor-specific
immune
responses.
Tumor
extracellular
vesicles
(TEVs)
are
nanoparticles
naturally
laden
with
tumor
antigens,
making
them
appealing
for
vaccine
development.
However,
their
inherent
malignant
properties
from
the
original
cells
limit
direct
therapeutic
use.
This
study
introduces
novel
approach
to
repurpose
TEVs
as
potent
personalized
vaccines.
The
shows
that
inhibition
of
both
YAP
and
autophagy
not
only
diminishes
malignancy-associated
traits
but
also
enhances
immunogenic
attributes
enriching
load
antigens
adjuvants.
These
revamped
TEVs,
termed
attenuated
yet
immunogenically
potentiated
(AI-TEVs),
showcase
potential
inhibiting
growth,
preventive
measure
possible
treatment
recurrent
cancers.
They
prompt
enduring
memory.
In
addition,
showing
AI-TEVs
can
counteract
growth
approach,
strategy
is
presented
developing
postoperative
that's
tailored
individual
patients.
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 4533 - 4568
Published: May 1, 2024
Until
now,
there
has
been
a
lack
of
effective
strategies
for
cancer
treatment.
Immunotherapy
high
potential
in
treating
several
cancers
but
its
efficacy
is
limited
as
monotherapy.
Chemoimmunotherapy
(CIT)
holds
promise
to
be
widely
used
Therefore,
identifying
their
involvement
and
synergy
CIT
approaches
decisive.
Nano-based
drug
delivery
systems
(NDDSs)
are
ideal
because
they
can
simultaneously
target
immune
cells
cells,
promoting
accumulation,
reducing
the
toxicity
drug.
In
this
review,
we
first
introduce
five
current
immunotherapies,
including
checkpoint
blocking
(ICB),
adoptive
cell
transfer
therapy
(ACT),
vaccines,
oncolytic
virus
(OVT)
cytokine
therapy.
Subsequently,
immunomodulatory
effects
chemotherapy
by
inducing
immunogenic
death
(ICD),
tumor
killer
infiltration,
down-regulating
immunosuppressive
inhibiting
checkpoints
have
described.
Finally,
NDDSs-mediated
collaborative
introduced
detail,
development
nanoparticles
prospected.
Journal of Translational Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Jan. 6, 2025
Immuno-oncology
has
witnessed
remarkable
advancements
in
the
past
decade,
revolutionizing
landscape
of
cancer
therapeutics
an
encouraging
manner.
Among
diverse
immunotherapy
strategies,
mRNA
vaccines
have
ushered
a
new
era
for
therapeutic
management
malignant
diseases,
primarily
due
to
their
impressive
impact
on
COVID-19
pandemic.
In
this
comprehensive
review,
we
offer
systematic
overview
vaccines,
focusing
optimization
structural
design,
crucial
role
delivery
materials,
and
administration
route.
Additionally,
summarize
preclinical
studies
clinical
trials
provide
valuable
insights
into
current
status
treatment.
Furthermore,
delve
discussion
significant
challenges
facing
development
tumor
vaccines.
These
encompass
both
intrinsic
external
factors
that
are
closely
intertwined
with
successful
application
innovative
approach.
To
pave
way
more
promising
future
treatments,
deeper
understanding
immunological
mechanisms,
increasing
number
high-quality
trials,
well-established
manufacturing
platform
crucial.
Collaborative
efforts
between
scientists,
clinicians,
industry
engineers
essential
achieving
these
goals.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(4), P. 1170 - 1170
Published: Feb. 11, 2025
Viral
infections
such
as
human
papillomavirus
(HPV)
and
Epstein–Barr
virus
(EBV)
play
a
critical
role
in
the
onset
of
oropharyngeal
(OPC)
nasopharyngeal
cancer
(NPC),
respectively.
Despite
advancements
targeted
therapies
immunotherapies,
recurrent/metastatic
setting,
these
tumors
remain
incurable
diseases
with
poor
prognosis.
The
development
therapeutic
tumor
vaccines,
utilizing
either
neoantigens
or
oncoviral
antigens,
represents
promising
addition
to
immunotherapy
arsenal.
Research
on
vaccine-based
for
OPC
NPC
focuses
targeting
viral
particularly
HPV
E6/E7
EBV
EBNA1/LMP2.
potential
vaccine
platforms,
including
peptide-based,
DNA,
RNA,
vector-based
induce
durable
immune
responses
against
antigens
is
reported.
early-phase
clinical
trials
evaluating
HPV-related
EBV-related
revealed
safety
preliminary
signs
efficacy;
however,
further
are
crucial
validation.
This
review
provides
an
overview
current
landscape
strategies
NPC,
discussing
their
biological
mechanisms
processes
involved
anti-HPV
anti-EBV
treatments,
particular
focus
factors
that
influence
therapies.
International Journal of Nanomedicine,
Journal Year:
2022,
Volume and Issue:
Volume 17, P. 869 - 900
Published: Feb. 1, 2022
Abstract:
Persistent
infection
with
high-risk
human
papillomaviruses
(HPVs),
such
as
HPV-16
and
HPV-18,
can
induce
cervical
cancer
in
humans.
The
disease
carries
high
morbidity
mortality
among
females
worldwide.
Inoculation
prophylactic
HPV
vaccines,
Gardasil
®
or
Cervarix
,
is
the
predominant
method
of
preventing
6
to
26
years
age.
However,
despite
availability
commercial
no
therapeutic
vaccines
eliminate
existing
infections
have
been
approved.
Peptide-based
which
form
one
most
potent
vaccine
platforms,
broadly
investigated
overcome
this
shortcoming.
are
especially
effective
inducing
cellular
immune
responses
eradicating
tumor
cells
when
combined
nanoscale
adjuvant
particles
delivery
systems.
This
review
summarizes
progress
development
peptide-based
nanovaccines
against
infection.
Keywords:
papillomavirus,
cancer,
nanovaccine
